News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rare Disease Drug Developer Ultragenyx Pharmaceuticals Jumps Toward $86 Million IPO


11/11/2013 7:46:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Capitalizing on two hot trends — rare disease drug development and Wall Street's resurgent interest in biotech companies — Ultragenyx Pharmaceutical Inc. filed plans Friday to raise $86.25 million through an initial public offering. The Novato company, which snagged the NASDAQ ticker symbol "RARE," has moved quickly in the so-called orphan disease space, which has garnered lots of attention over the past few years from Big Pharma and other investors. What's more, its IPO seizes on investors interest in life sciences stocks in general.

Help employers find you! Check out all the jobs and post your resume.

Read at San Francisco Business Times
Read at Nasdaq
Read at RTT News
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES